ácido aspártico

Aspartic Acid

1. Identity

Chemical Names and Classification

Aspartic acid (symbol Asp or D; known as aspartate in its anionic form) is an α-amino acid used in the biosynthesis of proteins. The L-isomer of aspartic acid is one of the 22 proteinogenic amino acids — the building blocks of proteins. Its systematic IUPAC name is 2-aminobutanedioic acid, which describes its structure as a four-carbon chain with amino and two carboxylic acid groups. It is also known colloquially as aminosuccinic acid. Its molecular formula is C₄H₇NO₄. Its molecular weight is 133.1 g/mol.

Aspartic acid is characterized by an acidic side chain that is negatively charged under biological conditions. It exists in both L- and D-forms and is involved in the formation of hydrogen bonds in proteins, contributing to asx turns (asx motifs).

Stereoisomers: L- and D-Forms

The name "aspartic acid" can refer to either enantiomer or a mixture of two. Of these two forms, only one, "L-aspartic acid," is directly incorporated into proteins. The biological roles of its counterpart, "D-aspartic acid," are more limited. Where enzymatic synthesis will produce one or the other, most chemical syntheses will produce both forms, "DL-aspartic acid," known as a racemic mixture.

Essential vs. Non-Essential Status

Aspartic acid is not an essential amino acid, which means that it can be synthesized from central metabolic pathway intermediates in humans and does not need to be present in the diet. First isolated in 1868 from legumin in plant seeds, aspartic acid is one of several so-called nonessential amino acids for mammals; that is, they can synthesize it from oxaloacetic acid (formed in the metabolism of carbohydrates) and do not require dietary sources.

Natural Sources

Aspartic acid is found in plants and animals, especially in sugar beets and sugar cane. Among animal-based sources, it is found in meat, poultry, eggs, and dairy products. Plant-based sources include soy products, legumes, and specific vegetables such as asparagus, avocados, and sugar beets. Dietary sources of aspartic acid include, but are not limited to, meat, sprouting seeds, oat flakes, avocado, and asparagus.

Biosynthesis in the Body

In the human body, aspartate is most frequently synthesized through the transamination of oxaloacetate. The biosynthesis of aspartate is facilitated by an aminotransferase enzyme: the transfer of an amine group from another molecule such as alanine or glutamine yields aspartate and an alpha-keto acid. Most L-Asp is synthesized by mitochondrial aspartate aminotransferase from oxaloacetate and glutamate acquired by glutamine deamidation, particularly in the liver and tumor cells, and transamination of branched-chain amino acids (BCAAs), particularly in muscles.

Common Forms and Preparations

Aspartic acid is available in several commercial and pharmaceutical forms:

• Free amino acid supplements — L-aspartic acid is available as a dietary supplement, often found in free-form amino acid supplements, workout powders, and wellness formulations.
• Mineral salt forms — Potassium and magnesium aspartates are salts of aspartic acid, an amino acid. They have been used as ergogenics, possibly by enhancing fatty acid metabolism and sparing muscle glycogen utilization or by mitigating the accumulation of ammonia during exercise.
• As a component of aspartame — Aspartame [L-aspartyl-L-phenylalanine methyl ester] is a dipeptide composed primarily of two amino acids, phenylalanine, and aspartic acid.
• Industrial/pharmaceutical production — Industrially, aspartate is produced by amination of fumarate catalyzed by L-aspartate ammonia-lyase. Currently, L-aspartic acid is produced by enzymatic conversion of fumaric acid and free ammonia using aspartase.
• Parenteral nutrition — Aspartic acid is an amino acid commonly found as a component in total parenteral nutrition.

2. Historical Discovery and Early Research

Aspartic acid was first discovered in 1827 by Auguste-Arthur Plisson and Étienne-Ossian Henry by hydrolysis of asparagine, which had been isolated from asparagus juice in 1806. Their original method used lead hydroxide, but various other acids or bases are now more commonly used instead. In the mid-19th century, aspartic acid was isolated directly from natural protein sources, with German chemist Karl Heinrich Ritthausen achieving the first such extraction in 1868 from the acid hydrolysis products of legumin, a protein found in plant seeds.

In 1827, chemists Auguste-Arthur Plisson and Étienne Ossian Henry isolated a new substance from asparagus juice, forever linking this amino acid to its botanical roots. The name "aspartic acid" itself is a nod to its origin, reflecting the tradition of naming chemicals after their sources.

The first modern scientific interest in aspartate as a physiological and potentially therapeutic agent dates to the mid-twentieth century. Aspartate has been regularly listed in exercise physiology textbooks as an ergogenic substance since the first known trial by Professor Henri Laborit's laboratory. Laborit's work in the late 1950s and early 1960s on the potassium and magnesium salts of aspartic acid as fatigue-recovery agents marked the beginning of applied supplementation research, with work by Shaw and Laborit on the treatment of fatigue with aspartic acid salts, and Laborit's U.S. patent for potassium aspartate and magnesium aspartate as a fatigue-recovery-promoting process, patented November 21, 1961.

Aspartic acid as a traditional botanical remedy in the sense of an intentionally used herbal medicine does not have a well-documented cross-cultural traditional use history — its discovery was a product of 19th-century European laboratory chemistry rather than traditional ethnobotanical practice. Its subsequent use in medicine and supplementation was driven by biochemical and physiological research rather than by any recorded folk or traditional medical tradition.

3. Key Biochemical Constituents and Mechanisms of Action

Central Metabolic Roles of L-Aspartic Acid

L-Asp has exceptional importance in urea synthesis, purine-nucleotide cycle (PNC), malate–aspartate shuttle (MAS), gluconeogenesis, and neurotransmission, and it is the substrate for the synthesis of proteins, asparagine, arginine, nucleotides, and of several substances that play a role in the development of nervous tissue and neurotransmission.

L-Asp transported via aspartate–glutamate carrier to the cytosol is used in protein and nucleotide synthesis, gluconeogenesis, urea, and purine-nucleotide cycles, and neurotransmission; and via the malate–aspartate shuttle it maintains NADH delivery to mitochondria and redox balance. L-Asp released from neurons connects with the glutamate–glutamine cycle and ensures glycolysis and ammonia detoxification in astrocytes. D-Asp has a role in brain development and hypothalamus regulation.

Urea Cycle and Ammonia Detoxification

Aspartic acid is involved in the urea cycle, assisting in the detoxification of ammonia by converting it into urea, which is then expelled by the kidneys. This process is critical for maintaining nitrogen balance in the body and preventing the toxic accumulation of ammonia, especially in the liver. The carboxylate anion of aspartic acid, aspartate, is a metabolite in the urea cycle and participates in gluconeogenesis.

Malate–Aspartate Shuttle

Aspartate carries reducing equivalents in the malate–aspartate shuttle, which utilizes the ready interconversion of aspartate and oxaloacetate, which is the oxidized (dehydrogenated) derivative of malic acid. This shuttle is critical for transferring NADH equivalents across the inner mitochondrial membrane, supporting aerobic energy production in cells.

Purine and Nucleotide Biosynthesis

Aspartate donates one nitrogen atom in the biosynthesis of inosine, the precursor to the purine bases. Aspartic acid is also the starting point for pyrimidine synthesis. Aspartic acid is a precursor to many amino acids and other molecules like asparagine, arginine, isoleucine, lysine, methionine, threonine, nucleotides, NAD, and pantothenate.

Neurotransmission

Aspartate (the conjugate base of aspartic acid) stimulates NMDA receptors, though not as strongly as the amino acid neurotransmitter L-glutamate does. Aspartate, like glutamine, can also be considered a neuroexcitatory neurotransmitter since it activates the N-methyl-D-aspartate (NMDA) receptor in the brain.

Role of Aspartate Aminotransferase (AST)

L-Asp concentrations in the blood are very low, and the main source of L-Asp is its synthesis by aspartate aminotransferase (AST) in most tissues. AST (L-aspartate-2-oxoglutarate aminotransferase, EC 2.6.1.1), formerly called glutamic oxaloacetic transaminase (GOT) and the well-known blood biochemical indicator of liver and heart injury, is a pyridoxal phosphate-dependent enzyme that catalyzes the interconversion of L-Asp and 2-oxoglutarate (2-OG) to oxaloacetate and glutamate (Glu).

Intestinal Absorption and Blood Levels

Under physiological conditions, most L-Asp obtained from food is transported through the apical membrane of enterocytes by SLC1A1 (EAAT3) and utilized for the synthesis of other amino acids (alanine, glutamate, proline, ornithine, and citrulline), nucleotides, and ATP. It has been shown that less than 1% of L-Asp administered alone or with 18 other amino acids plus glucose was recovered intact in intestinal blood. This means that orally consumed aspartic acid is largely metabolized within intestinal cells before reaching systemic circulation.

D-Aspartic Acid: Role and Origin

The main source of D-Asp is the racemization of L-Asp. D-Aspartic acid (D-Asp) is an endogenous amino acid occurring in several tissues and cells of both invertebrates and vertebrates. D-Asp was first detected in the brain and optic lobes of the cephalopod mollusk Octopus vulgaris and later in the nervous and endocrine systems of various animal phyla such as crustaceans, amphibians, reptiles, fish, chicken, rat, and man. In rat brain, D-Asp has been localized in various neurons, including the frontal cortex and hippocampus. In humans, D-Asp has been found in both fetal and adult brains as well as in the cerebrospinal fluid of adult individuals.

ATP Synthase Involvement

Aspartic acid acts as a hydrogen acceptor in a chain of ATP synthase.

Beta-Glucuronidase Inhibition

Dietary L-aspartic acid has been shown to act as an inhibitor of beta-glucuronidase, which serves to regulate enterohepatic circulation of bilirubin and bile acids.

4. Scientific Evidence by Area of Use

4.1 Exercise Performance and Anti-Fatigue (Potassium and Magnesium Aspartates)

The most extensively studied supplemental application for aspartate compounds is their use as ergogenic aids, primarily in the form of the potassium and magnesium salts of aspartic acid. Since the first observations of Laborit on aspartate and exercise in 1957, more than 20 studies were published on the effect of aspartate on exercise capacity in man and various animal species. The results of these studies are quite equivocal.

One positive trial: Seven healthy young male athletes exercised to exhaustion on a cycle ergometer after ingesting either the salts of aspartic acid or a placebo. Previous research had suggested that these salts can increase the capacity to perform muscular work by affecting circulating ammonia levels. The work test was performed at 75% of the subject's VO₂max after ingestion of 10 g of potassium-magnesium aspartate over a 24-hour period or a similar amount of placebo. A double-blind protocol was utilized. The time to exhaustion was significantly increased following aspartate ingestion: 87.6 ± 4.3 min vs. 75.7 ± 11.9 min in the placebo condition (p < .025). Free fatty acids were significantly increased post-exercise and lactate concentrations were decreased in the aspartate condition; there were also significant differences in ammonia levels after ingestion of aspartate at the 0, 15, 30, 45, and 60-minute collection periods.

However, the overall evidence base is mixed. Globally, studies with negative findings on endurance exercise were found in equal quantity to studies with positive results of aspartate on performance or its factors. In studies where an increase of endurance was observed in man, its magnitude was not related to the importance of the dosage, suggesting the absence of a biologic gradient. Studies on the effect of aspartate on ammonia level and performance during resistance exercise unanimously reported negative findings. This lack of effect could be the result of the difficulty for aspartate to access the cell compartment and the mitochondria in skeletal muscle.

Potassium and magnesium aspartates are salts of aspartic acid. They have been used as ergogenics, possibly by enhancing fatty acid metabolism and sparing muscle glycogen utilization or by mitigating the accumulation of ammonia during exercise. Claims of a glycogen-sparing action, reduced hyperammonaemia, and a higher rate of free fatty acid oxidation have not been confirmed unequivocally by the literature. To resolve the issue of the potential effect of aspartate on endurance performance, further research is needed, particularly regarding the effect of aspartate used in combinations.

Evidence strength: Mixed and inconclusive. Roughly half of studies report positive effects on endurance exercise and ammonia metabolism; the other half report no effect. Small sample sizes, variable dosing protocols, and the use of different salt forms limit conclusions. Resistance exercise studies are consistently negative.

4.2 D-Aspartic Acid and Testosterone / Reproductive Hormones

D-aspartic acid has attracted significant commercial interest as a testosterone-boosting supplement. The proposed mechanism involves the hypothalamic-pituitary-gonadal (HPG) axis. Data in mammalian studies indicate that DAA supplementation can influence the HPG axis at the level of the hypothalamus, anterior pituitary, and the testes. Accumulation of DAA at these sites is associated with an upregulation of testosterone production in these animals, as well as upstream effectors of the HPG axis.

D-aspartic acid is a physiological amino acid occurring principally in the pituitary gland and testes and has a role in the regulation of the release and synthesis of LH and testosterone in humans and rats.

One key early human study: Topo et al. demonstrated that after 12 days of supplementation (3.12 g/day), levels of testosterone were significantly increased by 42% (4.5–6.4 ng/mL). They recruited a cohort of healthy sedentary male IVF patients (27–37 years), with low initial testosterone levels (~4.55 ng/mL).

However, the systematic review of the totality of human evidence concludes differently: With 396 retrieved records, 23 animal studies and 4 human studies were included in one systematic review. In vivo and in vitro animal studies revealed the effect of D-Asp depending on species, sex, and organ. The review found that exogenous D-Asp enhances testosterone levels in male animal studies, whereas studies in humans yielded inconsistent results. The evidence for this association in man is still sparse, mostly because of limited number and poor quality studies.

A PLOS ONE randomized controlled trial in resistance-trained men reached a negative conclusion: Research on D-aspartic acid (DAA) has demonstrated increases in total testosterone levels in untrained men; however, research in resistance-trained men demonstrated no changes, and reductions in testosterone levels. The results suggest that changes in basal hormonal levels within the normal physiological range play a minor role with respect to training outcomes. The long-term effects of DAA did not provide any benefit in relation to strength or hypertrophy in a resistance-trained population. Additionally, DAA appears to be blunting neural adaptation that was evident in the placebo group. As such, the results of this study strongly suggest that DAA is not an ideal supplement for resistance-trained men and cannot be recommended for long-term use with resistance training.

A systematic review of randomized clinical trials in trained males specifically on body composition reported: Different doses of DAA (three grams, six grams, 7.12 grams, and 12 grams) in different intervention periods (two weeks, four weeks, and 12 weeks) have no effects on body composition in trained males. DAA supplementation is a low-level booster of testosterone and has no significant effect on the testosterone level in professional male athletes and cannot alter the body composition.

Evidence strength: Weak to inconclusive in humans, particularly in resistance-trained men. Animal models demonstrate a testosterone-stimulating effect; however, in humans the results are inconsistent. Benefits observed in some early trials involved sedentary men or those with subnormal baseline testosterone. Well-trained men appear not to benefit, and some data suggest a net negative effect.

4.3 Neurological Health and Brain Development

L-Asp released from neurons connects with the glutamate–glutamine cycle and ensures glycolysis and ammonia detoxification in astrocytes. D-Asp has a role in brain development and hypothalamus regulation. The role of aspartate as an endogenous excitatory neurotransmitter acting at NMDA receptors is well-established biochemically, but the clinical application of supplemental aspartate for neurological conditions does not yet have robust human clinical trial evidence.

The hereditary disorders in L-Asp metabolism include citrullinemia, asparagine synthetase deficiency, Canavan disease, and dicarboxylic aminoaciduria. L-Asp plays a role in the pathogenesis of psychiatric and neurologic disorders and alterations in BCAA levels in diabetes and hyperammonemia.

In the context of Canavan disease — a fatal neurological disorder — aspartoacylase catalyzes the deacetylation of N-acetylaspartic acid (NAA) to produce acetate and L-aspartate, and is the only brain enzyme that has been shown to effectively metabolize NAA. Although the exact role of this enzymatic reaction has not yet been completely elucidated, the metabolism of NAA appears to be necessary in the formation of myelin lipids, and defects in this enzyme lead to Canavan disease, a fatal neurological disorder. This pathological relationship underscores the importance of aspartate metabolism in myelin maintenance, though it is a disease-of-deficiency context rather than supplementation evidence.

Further research is needed to examine the targeting of L-Asp metabolism as a strategy to fight cancer, the use of L-Asp as a dietary supplement, and the risks of increased L-Asp consumption. The role of D-Asp in the brain warrants studies on its therapeutic potential in psychiatric disorders.

Evidence strength: Primarily mechanistic and preclinical. The neuroscience of aspartate is well-developed at the cellular and animal level, but there are currently insufficient human clinical trials to support claims that supplemental L- or D-aspartic acid meaningfully improves cognitive function, memory, or neurological disease outcomes in humans.

4.4 Liver Function and Ammonia Metabolism

Aspartate's role in the urea cycle positions it as theoretically relevant to liver function and ammonia clearance. A lower blood ammonia level during exercise was one effect attributed to aspartate administration. The involvement of aspartate in the urea cycle is another biologically plausible mechanism that could accelerate ammonia removal and, as a consequence, decrease the blood ammonia level. However, robust human clinical evidence specifically for liver health benefit from supplemental aspartate — independent of its mineral salt (potassium/magnesium aspartate) exercise context — is limited.

4.5 Cancer Metabolism (Preclinical/Emerging Research)

L-Asp has a crucial role in mitochondrial function and linking the reactions of amino acid catabolism, PNC, glycolysis, gluconeogenesis, protein synthesis, and cell proliferation. Due to the essential role of L-Asp in cell proliferation and reports of increased risk of cancer in subjects consuming higher amounts of aspartame, further research needs to examine strategies of targeting L-Asp metabolism to fight cancer and the influence of increased L-Asp consumption.

Evidence strength: Purely preclinical. The potential of targeting aspartate metabolic pathways in cancer is an area of active research but has not yet translated into clinical trials of aspartic acid supplementation for cancer outcomes.

5. Body Systems Associated with Aspartic Acid

• Central Nervous System: Acts as an excitatory neurotransmitter via NMDA receptor activation; involved in brain development and hypothalamus regulation (especially D-Asp); implicated in psychiatric and neurological disorders.
• Liver and Metabolic System: Central to the urea cycle and gluconeogenesis; synthesized primarily in the liver and crucial to hepatic nitrogen metabolism.
• Skeletal Muscle: Participates in the purine-nucleotide cycle; aspartate from BCAA transamination in muscle is an important nitrogen shuttle during exercise.
• Endocrine System: D-aspartic acid is found in the pituitary and testes; it is involved in LH and testosterone biosynthesis and release, though this effect in humans is inconsistent.
• Mitochondria and Energy Metabolism: The malate–aspartate shuttle depends on aspartate to transfer reducing equivalents for ATP synthesis.
• Immune System: L-Asp is the substrate for the synthesis of proteins, asparagine, arginine, nucleotides, and of several substances that play a role in the development of nervous tissue and neurotransmission. Arginine, downstream of aspartate, plays a recognized role in immune function.
• Gastrointestinal System: Under physiological conditions, most L-Asp obtained from food is transported through the apical membrane of enterocytes by SLC1A1 (EAAT3) and utilized for the synthesis of other amino acids, nucleotides, and ATP.

6. Dosage Forms and Dosages Reported in Studies

Dosages in the scientific literature vary considerably by form and application:

• Potassium-Magnesium Aspartate for exercise: One trial used 10 g of potassium-magnesium aspartate administered over a 24-hour period.
• D-Aspartic Acid for testosterone: Trials have examined different doses of DAA including 3 grams, 6 grams, 7.12 grams, and 12 grams, across different intervention periods of 2 weeks, 4 weeks, and 12 weeks.
• D-Aspartic Acid in the Topo et al. study: After 12 days of supplementation at 3.12 g/day, testosterone levels were significantly increased by 42%.

In clinical and hospital settings, aspartic acid is used as a component in total parenteral nutrition, where dosages are determined by individual patient requirements rather than fixed supplement doses.

7. Safety Considerations and Notable Interactions

Status as a Non-Essential Amino Acid

Aspartic acid is not an essential amino acid, which means that it can be synthesized from central metabolic pathway intermediates in humans and does not need to be present in the diet. Its endogenous synthesis means that dietary or supplemental deficiency is not a recognized clinical concern in healthy individuals.

Intestinal Uptake and Systemic Bioavailability

It has been shown that less than 1% of L-Asp administered alone or with 18 other amino acids plus glucose was recovered intact in intestinal blood. This low systemic bioavailability of orally administered L-aspartic acid raises important questions about the pharmacological relevance of supplementation and may partially explain the inconsistent clinical results seen in exercise and hormone trials.

Excitotoxicity Concern

Because aspartate is an NMDA receptor agonist — albeit weaker than glutamate — excessive concentrations in the brain raise theoretical concerns about excitotoxicity. In acute hyperammonaemia, activation of the NMDA receptor leads to excitotoxic cell death, changes in energy metabolism, and alterations in protein expression of the astrocyte that affect volume regulation and contribute to oedema. While this concern pertains to pathological hyperammonaemic states rather than normal dietary or supplemental intake, it is relevant to any clinical context involving elevated excitatory amino acid levels.

Hereditary Metabolic Disorders

The hereditary disorders in L-Asp metabolism include citrullinemia, asparagine synthetase deficiency, Canavan disease, and dicarboxylic aminoaciduria. In individuals with these rare inherited conditions, aspartate metabolism is disrupted in clinically significant ways. Canavan disease specifically involves a defect in the aspartoacylase enzyme; mutations that result in undetectable activity of aspartoacylase, which catalyzes the deacetylation of N-acetyl-L-aspartate, correlate with Canavan disease, a neurodegenerative disorder usually fatal during childhood.

Potential Interactions via Aspartame

Because aspartame is a direct dietary source of aspartic acid, considerations about high aspartame intake are relevant. Regulatory agencies such as the United States Food and Drug Administration (FDA) and the European Food Safety Authority have established acceptable daily intake (ADI) limits for aspartame, set at 50 mg/kg body weight in the United States and 40 mg/kg in Europe. Aspartic acid itself derived from high-dose aspartame consumption is one component of the broader debate about aspartame safety; however, the clinical significance of the aspartic acid component specifically, as distinct from phenylalanine or methanol, has not been independently resolved in human studies.

Amino Acid Regulatory Status

The FDA's position is that amino acids cannot be GRAS because there was a determination through public rule making that supported the agency's assessment that free amino acids are not GRAS. This means that in the United States, supplemental amino acids including aspartic acid are regulated as dietary supplements under DSHEA rather than as food additives with GRAS status, and evidence standards differ from those for pharmaceutical drugs.

Research Gaps and Unanswered Questions

The evidence for D-aspartic acid's effects on testosterone in humans is still sparse, mostly because of the limited number and poor quality of studies. There is an urgent need for more well-designed human clinical trials with larger sample sizes and longer duration. Further research is needed to examine the targeting of L-Asp metabolism as a strategy to fight cancer, the use of L-Asp as a dietary supplement, and the risks of increased L-Asp consumption.

References

• Holeček M. "Aspartic Acid in Health and Disease." Nutrients. 2023;15(18):4023. PMC/MDPI.
• Holeček M. "Aspartic Acid in Health and Disease." PubMed abstract. 2023.
• Melville GW, et al. "The putative effects of D-Aspartic acid on blood testosterone levels: A systematic review." PMC. 2017.
• Willoughby DS, Leutholtz B. "Three and six grams supplementation of d-aspartic acid in resistance trained men." PMC. 2015.
• Melville GW, et al. "The effects of d-aspartic acid supplementation in resistance-trained men over a three month training period: A randomised controlled trial." PLOS ONE. 2017.
• Topo E, et al. "The role and molecular mechanism of D-aspartic acid in the release and synthesis of LH and testosterone in humans and rats." PMC. 2009.
• Lak M, Goudarzi K, Shahrbaf MA. "D-aspartic Acid Supplementation Effects on Body Composition: A Systematic Review of Randomized Clinical Trials on Trained Males." Asian J Sports Med. 2022.
• Lamari Y, et al. "Effects of the Potassium and Magnesium Salts of Aspartic Acid on Metabolic Exhaustion." ScienceDirect. 2016.
• Wesson M, et al. "Effects of Oral Administration of Aspartic Acid Salts on the Endurance Capacity of Trained Athletes." Research Quarterly for Exercise and Sport. 1988.
• Aspartate as an Ergogenic Supplement. Sports Medicine. Springer. 2008.
• Williams MH. "Dietary Supplements and Sports Performance: Amino Acids." J Int Soc Sports Nutr. 2005.
• de Haan A, et al. "Effects of potassium + magnesium aspartate on muscle metabolism and force development during short intensive static exercise." PubMed. 1985.
• Aspartic acid — Wikipedia (chemistry and biosynthesis sections).
• Aspartic acid. Encyclopædia Britannica.
• Aspartic Acid — ScienceDirect Topics. Biochemistry Overview.
• L-Aspartic Acid. PubChem CID 5960. National Center for Biotechnology Information.
• Bhakta MN, et al. "Characterization of Human Aspartoacylase: the brain enzyme responsible for Canavan disease." PMC. 2008.
• Celik M, et al. "A Novel Mutation in Aspartoacylase Gene; Canavan Disease." PMC. 2015.
• Mutational Analysis of Aspartoacylase: Implications for Canavan Disease. PMC. 2007.
• U.S. Food and Drug Administration. "Aspartame and Other Sweeteners in Food." FDA.gov.
• Regulation of Amino Acids and Other Dietary Components Associated with Enhanced Physical Performance. NCBI Bookshelf.
• Neurological implications of urea cycle disorders. PMC. 2013.
• Asparagine — Wikipedia (history of isolation, 1806).